Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survival

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Chen, Guangdi ^a   Cheng, Yabin ^a   Zhang, Zhizhong ^a   Martinka, Magdalena ^a   Li, Gang ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

S PHASE KINASE ASSOCIATED PROTEIN 2; S PHASE KINASE ASSOCIATED PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL NUCLEUS; CHILD; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; DYSPLASTIC NEVUS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; MELANOMA; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHOOL CHILD; SKIN ULCER; TISSUE MICROARRAY; ADOLESCENT; ALGORITHM; COHORT ANALYSIS; DISEASE COURSE; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MORTALITY; SKIN TUMOR; SURVIVAL; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CHILD; COHORT STUDIES; CYTOPLASM; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELANOMA; MIDDLE AGED; S-PHASE KINASE-ASSOCIATED PROTEINS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; YOUNG ADULT;

EID: 79952229159     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017578     Document Type: Article

References (51)

1. Diepgen TL, Mahler V, (2002) The epidemiology of skin cancer. Br J Dermatol 146 (Suppl 61): 1-6.
2. Geller AC, Swetter SM, Brooks K, Demierre MF, Yaroch AL, (2007) Screening, early detection, and trends for melanoma: current status (2000-2006) and future directions. J Am Acad Dermatol 57: 555-572; quiz 573-556.
3. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648.
4. Houghton AN, Polsky D, (2002) Focus on melanoma. Cancer Cell 2: 275-278.
5. Trinh VA, (2008) Current management of metastatic melanoma. Am J Health Syst Pharm 65: S3-8.
6. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
7. Frescas D, Pagano M, (2008) Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 8: 438-449.
8. Ciechanover A, (1994) The ubiquitin-proteasome proteolytic pathway. Cell 79: 13-21.
9. Petroski MD, Deshaies RJ, (2005) Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6: 9-20.
10. Cardozo T, Pagano M, (2004) The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol 5: 739-751.
11. Skaar JR, D'Angiolella V, Pagan JK, Pagano M, (2009) SnapShot: F Box Proteins II. Cell 137: 1358, 1358 e1351.
12. Hershko DD, (2008) Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer 112: 1415-1424.
13. Li Q, Murphy M, Ross J, Sheehan C, Carlson JA, (2004) Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship. J Cutan Pathol 31: 633-642.
14. Woenckhaus C, Maile S, Uffmann S, Bansemir M, Dittberner T, et al. (2005) Expression of Skp2 and p27KIP1 in naevi and malignant melanoma of the skin and its relation to clinical outcome. Histol Histopathol 20: 501-508.
15. Chen G, Cheng Y, Martinka M, Li G, (2010) Cul1 expression is increased in early stages of human melanoma. Pigment Cell Melanoma Res 23: 572-574.
16. Dai DL, Martinka M, Li G, (2005) Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 23: 1473-1482.
17. Remmele W, Stegner HE, (1987) [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 8: 138-140.
18. Herlyn M, Clark WH, Rodeck U, Mancianti ML, Jambrosic J, et al. (1987) Biology of tumor progression in human melanocytes. Lab Invest 56: 461-474.
19. Houghton AN, Real FX, Davis LJ, Cordon-Cardo C, Old LJ, (1987) Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med 165: 812-829.
20. Govindarajan B, Bai X, Cohen C, Zhong H, Kilroy S, et al. (2003) Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem 278: 9790-9795.
21. Barnhill RL, Cerroni L, Cook M, Elder DE, Kerl H, et al. (2010) State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: outcome of an international workshop. Adv Anat Pathol 17: 73-90.
22. Friedman RJ, Farber MJ, Warycha MA, Papathasis N, Miller MK, et al. (2009) The "dysplastic" nevus. Clin Dermatol 27: 103-115.
23. Ibrahim N, Haluska FG, (2009) Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol 4: 551-579.
24. Crowson AN, Magro C, Miller A, Mihm MC Jr, (2007) The molecular basis of melanomagenesis and the metastatic phenotype. Semin Oncol 34: 476-490.
25. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, et al. (2001) Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A 98: 5043-5048.
26. Wellbrock C, Karasarides M, Marais R, (2004) The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5: 875-885.
27. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
28. Bhatt KV, Spofford LS, Aram G, McMullen M, Pumiglia K, et al. (2005) Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 24: 3459-3471.
29. Bhatt KV, Hu R, Spofford LS, Aplin AE, (2007) Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells. Oncogene 26: 1056-1066.
30. Motti ML, De Marco C, Califano D, De Gisi S, Malanga D, et al. (2007) Loss of p27 expression through RAS->BRAF->MAP kinase-dependent pathway in human thyroid carcinomas. Cell Cycle 6: 2817-2825.
31. Rose AE, Wang G, Hanniford D, Monni S, Tu T, et al. Clinical relevance of SKP2 alterations in metastatic melanoma. Pigment Cell Melanoma Res In press.
32. Tosco P, La Terra Maggiore GM, Forni P, Berrone S, Chiusa L, et al. Correlation between Skp2 expression and nodal metastasis in Stage I and II oral squamous cell carcinomas. Oral Dis In press.
33. Wang XC, Wu YP, Ye B, Lin DC, Feng YB, et al. (2009) Suppression of anoikis by SKP2 amplification and overexpression promotes metastasis of esophageal squamous cell carcinoma. Mol Cancer Res 7: 12-22.
34. Salon C, Merdzhanova G, Brambilla C, Brambilla E, Gazzeri S, et al. (2007) E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene 26: 6927-6936.
35. Einama T, Kagata Y, Tsuda H, Morita D, Ogata S, et al. (2006) High-level Skp2 expression in pancreatic ductal adenocarcinoma: correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome. Pancreas 32: 376-381.
36. Ma XM, Liu Y, Guo JW, Liu JH, Zuo LF, (2005) Relation of overexpression of S phase kinase-associated protein 2 with reduced expression of p27 and PTEN in human gastric carcinoma. World J Gastroenterol 11: 6716-6721.
37. Harada K, Supriatno, Kawaguchi S, Kawashima Y, Itashiki Y, et al. (2005) High expression of S-phase kinase-associated protein 2 (Skp2) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation. Anticancer Res 25: 2471-2475.
38. Yokoi S, Yasui K, Mori M, Iizasa T, Fujisawa T, et al. (2004) Amplification and overexpression of SKP2 are associated with metastasis of non-small-cell lung cancers to lymph nodes. Am J Pathol 165: 175-180.
39. Li JQ, Wu F, Masaki T, Kubo A, Fujita J, et al. (2004) Correlation of Skp2 with carcinogenesis, invasion, metastasis, and prognosis in colorectal tumors. Int J Oncol 25: 87-95.
40. Sumimoto H, Hirata K, Yamagata S, Miyoshi H, Miyagishi M, et al. (2006) Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi. Int J Cancer 118: 472-476.
41. Lin HK, Wang G, Chen Z, Teruya-Feldstein J, Liu Y, et al. (2009) Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol 11: 420-432.
42. Hung WC, Tseng WL, Shiea J, Chang HC, (2010) Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. Cancer Lett 288: 156-161.
43. Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, et al. (2007) Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 117: 719-729.
44. Hofmann UB, Houben R, Brocker EB, Becker JC, (2005) Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 87: 307-314.
45. Soengas MS, Lowe SW, (2003) Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151.
46. Li Y, McClay EF, (2002) Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 29: 413-426.
47. Chen G, Wang Y, Garate M, Zhou J, Li G, (2010) The tumor suppressor ING3 is degraded by SCF(Skp2)-mediated ubiquitin-proteasome system. Oncogene 29: 1498-1508.
48. Chen G, Li G, (2010) Increased Cul1 expression promotes melanoma cell proliferation through regulating p27 expression. Int J Oncol 37: 1339-1344.
49. Liu S, Yamauchi H, (2009) p27-Associated G1 arrest induced by hinokitiol in human malignant melanoma cells is mediated via down-regulation of pRb, Skp2 ubiquitin ligase, and impairment of Cdk2 function. Cancer Lett 286: 240-249.
50. Hu R, Aplin AE, (2008) Skp2 regulates G2/M progression in a p53-dependent manner. Mol Biol Cell 19: 4602-4610.
51. Katagiri Y, Hozumi Y, Kondo S, (2006) Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo. J Dermatol Sci 42: 215-224.